Charcot-Marie-Tooth (CMT) Market Outlook & Forecast: Advancing Pipelines, Genetic Innovation, and Market Opportunity | Thelansis

Executive Summary
Charcot-Marie-Tooth (CMT) disease is one of the most prevalent inherited neurological disorders globally, yet it remains one of the most underserved. Affecting nearly 2.6 million people worldwide and approximately 1 in 2,500 individuals, CMT causes progressive peripheral nerve degeneration, leading to debilitating muscle weakness, sensory loss, and mobility impairment, with no approved disease-modifying therapy in sight.

The field is now at a genuine inflection point. After years of stalled pipelines and supportive-care-only management, 2025-2026 has seen the first-ever Phase I trial of a peripherally restricted HDAC6 inhibitor, fresh Phase 2a data from NMD Pharma's ignaseclant program, and Novartis entering the gene therapy arena, signaling that the CMT landscape is shifting fast.

Thelansis Knowledge Partners has published its new comprehensive report: "Charcot-Marie-Tooth (CMT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036)". The report delivers deep, decision-ready intelligence across 8 major markets (8MM), the United States, EU5 (Germany, France, Italy, Spain, UK), Japan, and China, built for pharma and biotech executives navigating drug development, commercial strategy, and business development in this space.

Here is what the current CMT landscape looks like, and why the next 10 years matter more than ever.

Request a Free Sample of the Charcot-Marie-Tooth (CMT) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036: https://thelansis.com/reports/charcot-marie-tooth-cmt-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=cmt_mo

Key Emerging Players

The CMT pipeline has historically been thin, but 2025 and early 2026 have changed that story considerably. With 15+ emerging therapy candidates now in active development, and major names like Novartis entering the field, the competitive intensity is building quickly.

• Augustine Therapeutics (Belgium) dosed the first patient in a Phase I trial of AGT-100216 in May 2025 - the first-ever peripherally restricted, selective HDAC6 inhibitor to enter clinical development for CMT. The company secured an oversubscribed €78M Series A round, backed by Jeito Capital and Novo Holdings.
• NMD Pharma A/S (Denmark) received FDA Orphan Drug Designation for NMD670 (ignaseclant) in January 2025 and reported topline Phase 2a SYNAPSE-CMT results in February 2026. While the primary endpoint was not met, multiple pre-specified secondary endpoints showed improvement, keeping the program in active development.
• Novartis is progressing EDK060, a gene therapy candidate targeting specific CMT genetic subtypes, representing one of the highest-profile entries into the CMT space by a major pharma player.
• InFlectis BioScience is advancing IFB-088, a small molecule designed to restore myelination and improve nerve function by targeting the integrated stress response - with EMA orphan designation already secured.
• Elpida Therapeutics received USD 1.5M in funding from the CMT Research Foundation in September 2025 to advance manufacturing of ELP-02, an AAV-based gene therapy targeting CMT4J, with a Phase I/II trial now planned for 2026.
• Actio Biosciences (ABS-0871, TRPV4 inhibitor for CMT2C), ENCell Corp. (EN001), DTx Pharma, and Addex Therapeutics are among the other companies building out subtype-specific pipelines at various clinical and preclinical stages.

Thelansis's CMT report maps the full competitive landscape, clinical stage, mechanism of action, subtype targeting, regulatory milestones, and positioning, across all pipeline assets in the 8MM. This is the intelligence that helps BD and commercial teams move first.

Request a sample report for an in-depth analysis of key emerging players, pipeline staging, and mechanisms of action in Charcot-Marie-Tooth: https://thelansis.com/reports/charcot-marie-tooth-cmt-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=cmt_mo

Key Current Therapies & Standard of Care
There is no approved disease-modifying therapy for any subtype of CMT. Current management is multidisciplinary and focused entirely on symptom relief and preserving function:
• Physical and occupational therapy remain the cornerstone of CMT management - helping patients preserve mobility, build compensatory muscle strength, and slow functional decline over time.
• Ankle-foot orthoses (AFOs) and custom orthotics are widely used, particularly in patients with moderate-to-advanced disease, to correct foot drop and prevent falls.
• Surgical interventions, including tendon transfers and reconstructive procedures, are employed in select patients with significant foot deformities or joint instability.
• Pain management using pharmacologic approaches (anticonvulsants, tricyclic antidepressants) and non-pharmacologic therapies helps manage neuropathic pain, which is a significant quality-of-life burden for many CMT patients.
• Assistive devices and neurorehabilitation technologies, including functional electrical stimulation (FES) and wearable exoskeletons, are beginning to emerge as adjunctive tools to improve mobility outcomes.
• Off-label use of antioxidants such as alpha-lipoic acid and vitamin E is practiced in some settings for potential neuroprotective effects, though evidence remains limited.

The CMT1A subtype, driven by PMP22 gene duplication, accounts for the largest share of the diagnosed population and has historically been the primary target for drug development efforts. CMT1 overall represents over 52% of market revenue.

Thelansis's report provides a full current treatment landscape analysis, including physician prescribing behavior, line-of-therapy dynamics, KOL-perceived advantages and disadvantages of existing care approaches, and a forward-looking assessment of how emerging therapies will disrupt the current standard of care across all 8MM.

Request a sample now to explore the full Charcot-Marie-Tooth (CMT) treatment landscape and pipeline analysis: https://thelansis.com/reports/charcot-marie-tooth-cmt-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=cmt_mo

Key Market Drivers & Trends
The paradigm is shifting, from symptom management to precision, genetically targeted intervention.

The CMT market is in the early stages of a structural transformation, driven by several converging forces that are likely to define the next decade of commercial activity:

• Gene therapy and RNA-based approaches are moving toward clinical-stage validation. PMP22-silencing strategies for CMT1A, AAV-mediated gene replacement for CMT4J, and antisense oligonucleotide (ASO) programs are among the most closely watched modalities. These represent the clearest path to genuine disease modification.
• Next-generation genetic sequencing (NGS), including whole-exome (WES) and whole-genome sequencing (WGS), is enabling earlier and more precise diagnosis across CMT subtypes, a critical prerequisite for subtype-specific drug development and patient stratification in trials.
• Regulatory tailwinds are favorable. Multiple CMT candidates have received FDA Orphan Drug Designation, EMA Orphan Status, or are being evaluated under adaptive trial pathways, reducing regulatory risk and supporting pricing power.
• Multidisciplinary care is becoming the norm in leading CMT centers globally, with the July 2025 designation of MUSC as the first CMT Center of Excellence by the Charcot-Marie-Tooth Association reflecting this institutionalization of specialized care.
• Genotype-specific precision medicine strategies are gaining momentum. With CMT caused by mutations in 100+ genes, the shift toward subtype-targeted pipelines is creating a fragmented but highly specialized commercial opportunity - particularly attractive for rare disease-focused developers.
• China's role in the CMT market is growing, driven by expanding genetic testing infrastructure, improving rare disease regulatory frameworks, and a large undiagnosed patient population that represents a meaningful long-term commercial opportunity.

Thelansis CMT 2026-2036 report captures all of these dynamics with scenario-based market models, event impact analysis, and regional trend breakdowns.

Key Unmet Need & KOL Expectations
The unmet need in CMT is substantial and multi-layered. Despite growing pipeline activity, the gap between where patients are today and where they need to be remains wide:

• No approved disease-modifying therapy exists for any CMT subtype. Every patient is managing and not treating their disease. This is the single greatest unmet need in the space, and it defines the primary commercial opportunity for first movers.
• Delayed and missed diagnosis is a persistent structural problem. CMT is globally underdiagnosed, with wide variation in access to genetic testing and neurological expertise across markets. In many cases, patients go years without a confirmed genetic diagnosis - limiting eligibility for trials and future treatments.
• Validated biomarkers for tracking disease progression and treatment response are critically lacking. Without reliable biomarkers, efficient clinical trials remain a core challenge for developers.
• The genetic complexity of CMT (100+ causative genes) limits a one-size-fits-all approach and demands subtype-specific pipelines, which increases development costs and risk for smaller players without deep genomic expertise.
• KOLs are looking for therapies with a clear, genotype-confirmed target population, objective and validated functional endpoints (beyond the 10MWRT, which has since been removed from the CMT Functional Outcome Measure), and safety profiles suitable for long-term use, especially given the chronic and progressive nature of the disease.
• Patient quality of life, particularly the burden of foot deformities, falls, chronic fatigue, and pain is significantly underaddressed. Non-motor and patient-reported outcomes are increasingly becoming focal points in trial design and payer conversations.

Thelansis's CMT report includes detailed unmet need segmentation by subtype, primary research-backed KOL insights, and a Target Product Profile (TPP) analysis outlining what an ideal new therapy for CMT would look like, and where existing pipeline candidates stand relative to that benchmark.

Review the complete Charcot-Marie-Tooth (CMT) KOL survey findings and unmet need analysis: https://thelansis.com/reports/charcot-marie-tooth-cmt-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=cmt_mo

Commercial Opportunity
The commercial story in CMT is one of compounding tailwinds: a large, underserved patient population, no approved disease-modifying treatments, an accelerating pipeline, and favorable regulatory incentives, all converging across markets that are rapidly improving their rare disease infrastructure.

• The global CMT market is valued at approximately USD 1.6 billion in 2026, with projections indicating continued strong growth through 2030 and beyond, driven by the anticipated entry of first disease-modifying therapies.
• The United States accounts for the largest patient pool and market share (approximately 44% of global revenue), underpinned by strong research infrastructure, early trial access, and high diagnostic awareness. Thelansis projects over 138,000 prevalent CMT patients in the US in 2026, growing to approximately 148,500 by 2036, with the treated patient pool expanding from ~83,000 to ~98,000 over the same period.
• The EU5 markets, particularly Germany, France, and the UK, represent a significant secondary opportunity, supported by EMA orphan drug pathways, active KOL networks, and multidisciplinary CMT centers increasingly integrated into national rare disease programs.
• China is emerging as a critical market in the CMT commercial equation. Improving rare disease regulatory frameworks, large undiagnosed patient pools, and expanding genetic testing access create a substantial long-term opportunity, one that Thelansis specifically models in this report for the first time in its 8MM framework.
• CMT1A, the most prevalent subtype, will likely attract the first wave of commercial launches, with PMP22-targeting gene and RNA programs most advanced. CMT2 and CMTX subtypes present differentiated, less-competed niche opportunities as the market matures.

The Thelansis CMT 2026-2036 report delivers a complete commercial intelligence package: patient-based forecast models, market share scenarios, drug penetration curves, revenue projections, reimbursement landscape analysis, and payer insights - all calibrated to the 8MM, with country-level granularity.

CONTACT:
Himanshi Negi Manager - Global BD and Partnering
Thelansis Knowledge Partners
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.